HK Stock MarketDetailed Quotes

JUNSHI BIO (01877)

Watchlist
  • 22.600
  • -0.280-1.22%
Not Open May 19 16:00 CST
23.20BMarket Cap-32.71P/E (TTM)

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

JUNSHI BIO (01877) Revenue Breakdown Overview

By Business/Source

Currency:CNY
2025/FY
Stock NameRevenueRatio
Drug sales2.3B92.11%
许可收入160.84M6.44%
Service income33.82M1.35%
Other2.36M0.09%

By Product

Currency:CNY
2025/FY
Stock NameRevenueRatio
Drug sales2.3B92.11%
许可收入160.84M6.44%
Service income33.82M1.35%
Other2.36M0.09%

By Country/Region

Currency:CNY
2025/FY
Stock NameRevenueRatio
China Mainland2.31B92.42%
United States of America91.87M3.68%
Other71.71M2.87%
India25.72M1.03%

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Market Insights
Petroleum
No. Symbol 20D % Chg
Sample Name
Sample Code
 +7.54%
Sample Name
Sample Code
 +4.71%
Sample Name
Sample Code
 0.00%
4
SHANGHAI PECHEM
00338
-0.81%
5
SINOPEC CORP
00386
-0.88%
View More
No. Symbol 20D % Chg
Sample Name
Sample Code
 +42.01%
Sample Name
Sample Code
 +32.82%
Sample Name
Sample Code
 +26.86%
4
Emdoor Information
001314
+25.83%
5
Digital China Group
000034
+20.88%
View More
China and the US begin implementing the Kuala Lumpur economic and trade consultation consensus.
China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome Show More
[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?
"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"

- No more -